tetano
Editor, Senior Moderator
PLoS One
. 2025 Apr 28;20(4):e0320744.
doi: 10.1371/journal.pone.0320744. eCollection 2025. Impact of memory T cells on SARS-CoV-2 vaccine response in hematopoietic stem cell transplant
Jennifer VanOudenhove[SUP] 1 [/SUP], Yuxin Liu[SUP] 1 [/SUP], Raman Nelakanti[SUP] 1 [/SUP], Dongjoo Kim[SUP] 2 [/SUP], Emma Busarello[SUP] 3 [/SUP], Natalia Tijaro Ovalle[SUP] 4 [/SUP], Zhihong Qi[SUP] 1 [/SUP], Padmavathi Mamillapalli[SUP] 1 [/SUP], Alexa Siddon[SUP] 5 [/SUP], Zhiliang Bai[SUP] 2 [/SUP], Alfredo Axtmayer[SUP] 6 [/SUP], Cheryl Corso[SUP] 6 [/SUP], Shalin Kothari[SUP] 1 [/SUP], Francine Foss[SUP] 1 [/SUP], Iris Isufi[SUP] 1 6 [/SUP], Toma Tebaldi[SUP] 3 [/SUP], Lohith Gowda[SUP] 1 [/SUP], Rong Fan[SUP] 2 [/SUP], Stuart Seropian[SUP] 1 [/SUP], Stephanie Halene[SUP] 1 7 [/SUP]
Affiliations
During the COVID-19 pandemic, hematopoietic stem cell transplant (HSCT) recipients had elevated mortality rates from SARS-CoV-2 infection, ranging between 10-40%. SARS-CoV-2 mRNA vaccines are important tools in preventing severe disease, yet their efficacy post-transplant remains unclear, especially in patients subjected to myeloablative chemotherapy and immunosuppression. We evaluated humoral and adaptive immune responses to the SARS-CoV-2 mRNA vaccination series in 42 HSCT recipients and 5 healthy controls. Post-vaccination responses were assessed by anti-spike IgG and nucleocapsid levels, and antigen specific T cell activity. Immune profiling was performed using clinical flow and mass cytometry. Patients were selected based on humoral and cellular responses for single-cell RNA with TCR and BCR sequencing. Our studies revealed defects in memory T cells that correlated with an absence of cellular response despite nearly universal humoral response. Several patients with a robust antibody response developed COVID-19 infection, but none developed severe disease or died from the infection.
. 2025 Apr 28;20(4):e0320744.
doi: 10.1371/journal.pone.0320744. eCollection 2025. Impact of memory T cells on SARS-CoV-2 vaccine response in hematopoietic stem cell transplant
Jennifer VanOudenhove[SUP] 1 [/SUP], Yuxin Liu[SUP] 1 [/SUP], Raman Nelakanti[SUP] 1 [/SUP], Dongjoo Kim[SUP] 2 [/SUP], Emma Busarello[SUP] 3 [/SUP], Natalia Tijaro Ovalle[SUP] 4 [/SUP], Zhihong Qi[SUP] 1 [/SUP], Padmavathi Mamillapalli[SUP] 1 [/SUP], Alexa Siddon[SUP] 5 [/SUP], Zhiliang Bai[SUP] 2 [/SUP], Alfredo Axtmayer[SUP] 6 [/SUP], Cheryl Corso[SUP] 6 [/SUP], Shalin Kothari[SUP] 1 [/SUP], Francine Foss[SUP] 1 [/SUP], Iris Isufi[SUP] 1 6 [/SUP], Toma Tebaldi[SUP] 3 [/SUP], Lohith Gowda[SUP] 1 [/SUP], Rong Fan[SUP] 2 [/SUP], Stuart Seropian[SUP] 1 [/SUP], Stephanie Halene[SUP] 1 7 [/SUP]
Affiliations
- PMID: 40294012
- DOI: 10.1371/journal.pone.0320744
During the COVID-19 pandemic, hematopoietic stem cell transplant (HSCT) recipients had elevated mortality rates from SARS-CoV-2 infection, ranging between 10-40%. SARS-CoV-2 mRNA vaccines are important tools in preventing severe disease, yet their efficacy post-transplant remains unclear, especially in patients subjected to myeloablative chemotherapy and immunosuppression. We evaluated humoral and adaptive immune responses to the SARS-CoV-2 mRNA vaccination series in 42 HSCT recipients and 5 healthy controls. Post-vaccination responses were assessed by anti-spike IgG and nucleocapsid levels, and antigen specific T cell activity. Immune profiling was performed using clinical flow and mass cytometry. Patients were selected based on humoral and cellular responses for single-cell RNA with TCR and BCR sequencing. Our studies revealed defects in memory T cells that correlated with an absence of cellular response despite nearly universal humoral response. Several patients with a robust antibody response developed COVID-19 infection, but none developed severe disease or died from the infection.